Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 9:49:101172.
doi: 10.1016/j.lanepe.2024.101172. eCollection 2025 Feb.

HBV and HCV testing outcomes among marginalized communities in Italy, 2019-2024: a prospective study

Monica Monti  1 , Teresita Caruso  1   2 , Alice Castellaccio  3 , Irene De Giorgi  1   2 , Gabriella Cavallini  2 , Maria Laura Manca  4 , Serena Lorini  1 , Silvia Marri  5 , Luisa Petraccia  6 , Francesco Madia  1 , Cristina Stasi  7   8 , Laura Carraresi  5 , Elisabetta Lorefice  9 , Sara Irene Bonelli  3 , Alessandro Nerli  10 , Mouheb M A Mudalal  1 , Lorenzo Martini  1 , Stefano Gitto  1 , Eleonora Carradori  1 , Adela Xheka  1 , Irene Bendini  1 , Samuele Lukolic'  11 , Lorenzo Latella  11 , Donatella Aquilini  10 , Pierluigi Blanc  3 , Anna Linda Zignego  1 , Laura Gragnani  2
Affiliations

HBV and HCV testing outcomes among marginalized communities in Italy, 2019-2024: a prospective study

Monica Monti et al. Lancet Reg Health Eur. .

Abstract

Background: The health of the marginalized populations is crucial for public health and inequalities. The World Health Organization (WHO) Global Hepatitis Report 2024 stated that over 304 million people were living with Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) infection in 2022. We performed HBV/HCV screenings among marginalized communities to reveal hidden infections and link-to-care positive participants.

Methods: From January 2019 to May 2024, finger-prick tests were used to conduct on-site screenings at non-profit organizations in Tuscany, Italy. Positive participants were referred to the closest outpatient clinic.

Findings: Eighty/1812 (4.4%) participants were Hepatitis B surface Antigen (HBsAg)+, mostly men (p < 0.001) and non-Italian natives compared to those HBsAg- (p < 0.001). Fifty-two/1812 (2.9%) were anti-HCV+ with a higher proportion of Italians (p < 0.001) and lower education level (p < 0.01) compared to the anti-HCV-. Intravenous drug use was an independent factor for being anti-HCV+ (p < 0.0001). Among the HBsAg + individuals, 66.3% (53/80) were linked and 90.4% (48/53) retained in care (treated/monitored). Of the anti-HCV participants requiring clinical evaluation, 37.8% (14/37) were linked to care, and all the 11/14 (88.6%) viremic patients were successfully treated.

Interpretation: We found higher HBV/HCV positivity compared to national prevalences. Participation and linkage to care were successful. The young mean age (33.6 yrs) of HBsAg + individuals, primarily from regions with low vaccinal adherence, indicated geographical origin as a key risk factor. HCV positivity was associated with extreme marginality. The results stress the need to implement marginalized groups screening to target HBV/HCV hidden infections, reducing disparities in healthcare and advancing towards the WHO 2030 elimination goal.

Funding: Gilead Sciences; Fondazione Cassa di Risparmio di Pistoia e Pescia; Regione Toscana.

Keywords: Healthcare disparities; Hepatitis B virus; Hepatitis C virus; Marginalized populations; World Health Organization.

PubMed Disclaimer

Conflict of interest statement

Stefano Gitto: Gilead, speaker honoraria (2, year 2024), consultant fee (1, year 2024). All other authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart summarizing the study outcomes.
Fig. 2
Fig. 2
Geographical origin of participants.
Fig. 3
Fig. 3
Geographical origin of the HBsAg positive and anti-HCV-positive individuals, based on World regions classified according to the United Nation Geoscheme.
See this image and copyright information in PMC

References

    1. Sharma S., Carballo M., Feld J.J., Janssen H.L. Immigration and viral hepatitis. J Hepatol. 2015;63(2):515–522. doi: 10.1016/j.jhep.2015.04.026. - DOI - PubMed
    1. Burki T. WHO's 2024 global hepatitis report. Lancet Infect Dis. 2024;24(6):e362–e363. doi: 10.1016/S1473-3099(24)00307-4. - DOI - PubMed
    1. Vogel A., Meyer T., Sapisochin G., Salem R., Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362. doi: 10.1016/S0140-6736(22)01200-4. - DOI - PubMed
    1. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538. doi: 10.1016/j.jhep.2006.05.013. - DOI - PubMed
    1. Smith S., Harmanci H., Hutin Y., et al. Global progress on the elimination of viral hepatitis as a major public health threat: an analysis of WHO Member State responses 2017. JHEP Rep. 2019;1(2):81–89. doi: 10.1016/j.jhepr.2019.04.002. - DOI - PMC - PubMed

LinkOut - more resources